IP Library Granted Patent US 9,902,745
Granted Patent B2
US 9,902,745 · App. 15/343,967 · Granted Feb 27, 2018

High-purity large-scale preparation of stannsoporfin

Inventors: George S. Drummond (New York, NY); Robert Caroselli (East Brunswick, NJ); Keith A. Cooke (Milton, CA); Daniel Levin (Toronto, CA); David G. Roe (Rockwood, CA); Christopher P. Boucher (Newmarket, CA)
Assignee: INFACARE PHARMACEUTICAL CORPORATION
C07F7/2284A61K9/0019A61K31/555C07D487/22C07F7/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,745
App. No.
15/343,967
Granted
Feb 27, 2018
Kind
B2
Abstract

Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.

Claims (24)

1. A method of making stannsoporfin comprising:

a. exposing a metallic hydrogenation catalyst to a hydrogen atmosphere to form pre-hydrogenated catalyst;

b. contacting hemin with the pre-hydrogenated catalyst to form mesoporphyrin IX or salt thereof;

c. contacting a solution or suspension of tin (II) oxide or tin (II) salt with the mesoporphyrin IX or salt thereof under conditions suitable to form stannsoporfin.

2. The method of claim 1 further comprising step d) purifying the stannsoporfin via hot acid trituration, followed by treatment at high pH at or above pH 9 followed by re-acidification, and subsequent hot acid trituration.

3. The method of claim 1 , further comprising, after step b., a step b1) of isolating the mesoporphyrin IX or salt thereof as mesoporphyrin IX formate.

4. The method of claim 3 , further comprising, after step b1), an additional step b2) of purifying the mesoporphyrin IX formate.

5. The method of claim 3 , further comprising, after step b1), a step of b2) converting the mesoporphyrin IX formate into mesoporphyrin IX dihydrochloride.

6. The method of claim 3 , further comprising after step b1) the steps of: b2) treating the mesoporphyrin IX formate with diatomaceous earth, activated carbon, and formic acid to form a mesoporphyrin IX formate suspension in formic acid; b3) filtering the mesoporphyrin IX formate suspension in formic acid to form a formic acid solution of mesoporphyrin IX formate; b4) adding a 1N hydrochloric acid solution to the solution of mesoporphyrin IX formate to form a mesoporphyrin IX dichloride.

7. The method of claim 6 wherein the adding the 1N hydrochloric acid solution comprises: adding a first portion of the 1N hydrochloric acid solution; adding mesoporphyrin IX dichloride seed crystals with agitation; and adding a second portion of the 1N hydrochloric acid solution with vigorous stirring.

8. The method of claim 1 , wherein the metallic hydrogenation catalyst is selected from the group consisting of palladium, palladium on carbon, platinum, platinum on carbon, nickel and nickel-aluminum.

9. The method of claim 8 , wherein the metallic hydrogenation catalyst is palladium on carbon.

10. The method of claim 1 , wherein the exposing in step a. comprises adding formic acid to the metallic hydrogenation catalyst under a nitrogen atmosphere to form a metallic hydrogenation suspension, replacing the nitrogen atmosphere with the hydrogen atmosphere, and adjusting the temperature of the metallic hydrogenation suspension to 80-90° C. for about 1-3 hours to form the pre-hydrogenated catalyst; wherein the metallic hydrogenation catalyst is palladium on carbon, and the hydrogen atmosphere is 50-70 psi.

11. The method of claim 1 , wherein in step c., the solution or suspension of tin (II) oxide is a tin (II) oxide formic acid solution or suspension or a tin (II) oxide acetic acid solution or suspension and wherein the mesoporphyrin IX or salt thereof is first converted to a mesoporphyrin IX or salt thereof formic acid solution or suspension or a mesoporphyrin IX or salt thereof acetic acid solution or suspension by the addition of formic acid or acetic acid.

12. The method of claim 11 wherein the mesoporphyrin IX or salt thereof formic acid solution or suspension or the mesoporphyrin IX or salt thereof acetic acid solution or suspension is added to the tin (II) oxide formic acid solution or suspension or the tin (II) oxide acetic acid solution or suspension.

13. The method of claim 12 wherein the mesoporphyrin IX or salt thereof formic acid solution or suspension is added over a period of 3-9 hours; the tin (II) oxide acetic acid solution or suspension is maintained at a temperature of 25-115° C. and the contacting is maintained for an additional 2 to 48 hours after the mesoporphyrin IX or salt thereof formic acid solution or suspension is added.

14. The method of claim 1 , wherein in step c. the contacting comprises treating the mesoporphyrin IX or salt thereof with a solution or suspension of tin (II) salt in an organic solvent under oxidizing conditions to form stannsoporfin.

15. The method of claim 12 , wherein the treating comprises heating the mesoporphyrin IX or salt thereof and the solution or suspension of tin(II) salt in the organic solvent to reflux, in a reaction vessel with vigorous agitation, then introducing a 6% oxygen in nitrogen atmosphere to the vessel and maintaining reflux for 100-130 hours to form the stannsoporfin; wherein the tin (II) salt is SnCl 2 , and the solvent is acetic acid.

16. A method of making stannsoporfin comprising:

a. adding formic acid to palladium on carbon under a nitrogen atmosphere to form a palladium on carbon suspension; replacing the nitrogen atmosphere with a hydrogen atmosphere of 50-70 psi, and adjusting the temperature of the palladium on carbon suspension to 80-90° C. for about 1-3 hours to form a pre-hydrogenated palladium on carbon catalyst in formic acid;

b. contacting hemin with the pre-hydrogenated palladium on carbon catalyst in formic acid to form mesoporphyrin IX formate; treating the mesoporphyrin IX formate with diatomaceous earth, activated carbon, and formic acid to form a mesoporphyrin IX formate suspension in formic acid; filtering the mesoporphyrin IX formate suspension in formic acid to form a formic acid solution of mesoporphyrin IX formate;

c. adding a first portion of the 1N hydrochloric acid solution to the mesoporphyrin IX formate suspension in formic acid; adding mesoporphyrin IX dichloride seed crystals with agitation; and adding a second portion of the 1N hydrochloric acid solution with vigorous stirring to form a mesoporphyrin IX dichloride;

d. treating the mesoporphyrin IX dichloride with formic acid to form a mesoporphyrin IX dichloride formic acid solution; adding the mesoporphyrin IX dichloride formic acid solution over a period of 3-9 hours to a tin (II) oxide acetic acid solution or suspension that is maintained at 25-115° C. with stirring to form a reaction mixture; maintaining the reaction mixture for an additional 2 to 48 hours to form the stannsoporfin;

e. purifying the stannsoporfin via hot acid trituration, followed by treatment at high pH at or above pH 9 followed by re-acidification, and subsequent hot acid trituration.

Assignments (17)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 075393/0058 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044173, FRAME 0574 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0128 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0454 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049822/0674 →
NUNC PRO TUNC ASSIGNMENT Recorded May 24, 2019
From: MALLINCKRODT IP UNLIMITED COMPANY
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 049274/0983 →
NUNC PRO TUNC ASSIGNMENT Recorded May 24, 2019
From: MALLINCKRODT PHARMA IP TRADING D.A.C.
To: MALLINCKRODT IP UNLIMITED COMPANY
Reel/Frame 049274/0954 →
NUNC PRO TUNC ASSIGNMENT Recorded May 24, 2019
From: INFACARE PHARMACEUTICAL CORPORATION
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 049274/0943 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Oct 10, 2017
From: INFACARE PHARMACEUTICAL CORPORATION
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044173/0574 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2016
From: DRUMMOND, GEORGE S.; CAROSELLI, ROBERT; COOKE, KEITH A.; LEVIN, DANIEL; ROE, DAVID G.; BOUCHER, CHRISTOPHER P.
To: INFACARE PHARMACEUTICAL CORPORATION
Reel/Frame 040831/0919 →
Continuity (8)
Continuation 14793921 · Jul 8, 2015
Continuation 14460080 · Aug 14, 2014
Continuation 14019513 · Sep 5, 2013
Continuation 12968651 · Dec 15, 2010
Continuation 11867559 · Oct 4, 2007
Provisional Application 60904601 · Feb 28, 2007
Provisional Application 60849641 · Oct 4, 2006
Related Publication 20170073362A1 · Mar 16, 2017